Dose–response experiments demonstrated that HDAC inhibitors decrease Ewing sarcoma cell proliferation in 72-hour cell growth assays, consistent with the established role of these genes in cell survival and published work on the sensitivity of Ewing sarcoma cell lines to HDAC inhibitors (Supplementary Fig. S1; refs. 59–64). The gene discussed is HDAC9; the disease is Ewing sarcoma.